The first trailer for Prime Video’s Spider-Noir has arrived, introducing fans to a superhero that’s more gumshoe than he is Avenger. Oh, and he just so happens to be played by Nicolas Cage. The new ...

Greetings, and welcome to the Incyte's Fourth Quarter and Year-End 2025 Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.

Check out some of the companies making the biggest moves midday: Amentum Holdings — The defense contractor tumbled about 12% after fiscal first-quarter revenue and adjusted EBITDA missed Wall Street ...

We’re a getting a peek at the characters in Prime Video‘s upcoming live-action series Spider-Noir, starring Nicolas Cage in his first leading television role. The streamer has dropped several ...

Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), setting up a potential label expansion for the drug as a first-line option ...

As of December 6, 2025, the average one-year price target for Incyte is $96.26/share. The forecasts range from a low of $70.70 to a high of $131.25. The average price target represents a decrease of 6 ...

Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Incyte Corporation’s (NASDAQ:INCY) announced Opzelura (ruxolitinib) cream 1.5% for the short-term and non-continuous chronic treatment ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Saturday. Other ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Incyte Corporation is one of them. Incyte Corporation (NASDAQ:INCY), a global biopharmaceutical ...